Eastern Hepatobiliary Surgery Hospital
🇨🇳China
Clinical Trials
68
Active:1
Completed:38
Trial Phases
4 Phases
Phase 1:5
Phase 2:14
Phase 4:6
+1 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (59 trials with phase data)• Click on a phase to view related trials
Not Applicable
34 (57.6%)Phase 2
14 (23.7%)Phase 4
6 (10.2%)Phase 1
5 (8.5%)A Clinical Study of Multi-target Hi-TCR-T Cells in the Treatment of Advanced Hepatocellular Carcinoma
Phase 1
Recruiting
- Conditions
- Advanced Hepatocellular Carcinoma (HCC)
- Interventions
- Biological: Super Hi-TCR-T cells
- First Posted Date
- 2025-03-30
- Last Posted Date
- 2025-09-03
- Lead Sponsor
- Eastern Hepatobiliary Surgery Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT06902389
- Locations
- 🇨🇳
The Third Affiliated Hospital of Navy Military Medical University, Shanghai, Yangpu District, China
QL1706 Combined With Lenvatinib and GEMOX as First - Line Treatment for Unresectable Biliary Tract Tumors
- First Posted Date
- 2025-03-25
- Last Posted Date
- 2025-07-10
- Lead Sponsor
- Eastern Hepatobiliary Surgery Hospital
- Target Recruit Count
- 59
- Registration Number
- NCT06892925
- Locations
- 🇨🇳
the Third Affiliated Hospital of Naval Medical University, Shanghai, Shanghai, China
Inetetamab Plus Chemotherapy ± PD-1/PD-L1 in HER2+ Advanced Biliary Cancer
Phase 4
Not yet recruiting
- Conditions
- Metastatic Biliary Tract CancerHER2 Positive
- Interventions
- Drug: Inetetamab + Gemcitabine + Cisplatin ± PD-1/PD-L1 inhibitor
- First Posted Date
- 2025-02-10
- Last Posted Date
- 2025-02-10
- Lead Sponsor
- Eastern Hepatobiliary Surgery Hospital
- Target Recruit Count
- 35
- Registration Number
- NCT06818773
Pemigatinib Combined With Durvalumab for Previously Treated Biliary Tract Carcinoma
Phase 2
Not yet recruiting
- Conditions
- Biliary Tract CarcinomaCholangiocarcinoma
- Interventions
- First Posted Date
- 2024-07-31
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- Eastern Hepatobiliary Surgery Hospital
- Target Recruit Count
- 38
- Registration Number
- NCT06530823
Envafolimab Combined With GEMOX in First-line Treatment of Advanced GBC
Phase 2
Recruiting
- Conditions
- Gallbladder Cancer
- Interventions
- Drug: Envafolimab+Gemox
- First Posted Date
- 2023-08-28
- Last Posted Date
- 2023-09-15
- Lead Sponsor
- Eastern Hepatobiliary Surgery Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT06013943
- Locations
- 🇨🇳
Easter hepatobiliary surgery hospital, Shanghai, Shanghai, China
- Prev
- 1
- 2
- 3
- 4
- 5
- 13
- Next
News
No news found